OnabotulinumtoxinA (VA Office of Research and Development)

- Provides Revance entry into the $2.5 billion U.S. therapeutic neuromodulator market. 1 - Approval expands the DAXXIFY® label to include efficacy data over the 52-week ASPEN repeat dose clinical study. - DAXXIFY® for cervical dystonia is the first and only peptide-formulated, long-lasting neuromodulator, designed to meet the needs of patients seeking improved treatment outcomes. 2-5 - 88% of U.S. cervical dystonia patients experience symptom reemergence eight to 10 weeks after conventional neuromodulator treatment. 6 NASHVILLE, TN, USA I August 14, 2023 I Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved the first therapeutic indication for DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults. 7 DAXXIFY® , powered by Peptide Exchange Technology™, was previously approved by the FDA for the temporary improvement of glabellar lines (frown lines) in adults in September 2022 and is the first true innovation in neuromodulator product formulation in more than 30 years. 8-11 “We are very pleased to see the expansion of the DAXXIFY® label to include our first therapeutic indication, unlocking a new market opportunity for DAXXIFY® following the product’s recent launch in the aesthetics market. Further, we believe FDA approval represents a significant advancement in the treatment of cervical dystonia” Tweet this Cervical dystonia is a chronic, debilitating disease in which the neck muscles contract involuntarily, causing abnormal movements, pain and awkward posture of the head and neck. 12,13 Neuromodulators are considered the first line of treatment for this condition, which effects roughly 60,000 Americans. In 2017, the U.S. FDA granted orphan drug designation to DAXXIFY® for the treatment of cervical dystonia in adults. “We are very pleased to see the expansion of the DAXXIFY® label to include our first therapeutic indication, unlocking a new market opportunity for DAXXIFY® following the product’s recent launch in the aesthetics market. Further, we believe FDA approval represents a significant advancement in the treatment of cervical dystonia,” said Chief Executive Officer Mark J. Foley. “DAXXIFY’s differentiated efficacy, duration and safety profile can help physicians deliver long-lasting symptom relief to patients suffering from cervical dystonia, while also helping payers address the total cost of care for this population. We look forward to conducting our early experience and education program, PrevU, which will involve a small group of thought leaders, followed by a progressive commercial rollout beginning in 2024. Today’s approval is an important milestone for Revance, marking the start to our therapeutics franchise.” Peter McAllister, M.D., ASPEN investigator and co-founder and medical director of the New England Institute for Neurology and Headache, commented: “As an ASPEN investigator, I am excited to see the approval of a new treatment option to address symptom reemergence prior to retreatment, a common issue for cervical dystonia patients. Currently, patients experience painful and life-limiting symptom recurrence as early as eight to 10 weeks in clinical practice but cannot be re-treated until 12 weeks. DAXXIFY® is the first long-acting neuromodulator that has the potential to address this significant unmet need -- demonstrating durable symptom relief between treatment cycles and providing the opportunity to extend treatment intervals.” The U.S. approval of DAXXIFY® for the treatment of cervical dystonia in adults was based on data generated in the Phase 3 clinical program ( ASPEN 1 , ASPEN OLS ), which included 382 patients and 1,240 treatments across up to five injection cycles over an 88-week time span, based on the masked, randomized ASPEN-1 and ASPEN Open Label Study (OLS). 2-5 In the pivotal ASPEN clinical study, DAXXIFY® was shown to be effective, generally safe, and well tolerated across both dose groups, 125U and 250U, with a median duration of effect of 24.0 and 20.3 weeks for the two dose groups respectively. 2-3,14-15* Based on the ASPEN OLS study, symptoms continued to improve with successive DAXXIFY® treatments at doses up to 300U, while adverse events remained low. 15-16 In particular, dysphagia rates (difficulty swallowing) remained low (2.7% for ASPEN-1 and 4.2% for ASPEN-OLS), further supporting DAXXIFY’s safety profile. 15-16 The total U.S. therapeutic neuromodulator market opportunity for DAXXIFY® is $2.5 billion, which includes the $345 million cervical dystonia market. 1 Providers and patients interested in receiving more information on DAXXIFY® are encouraged to visit https://hcp.daxxify.com/ . *Median duration of effect was defined as time from treatment until loss of ≥80% of the peak effect (change from baseline in TWSTRS total score averaged across weeks four and six). DAXXIFY ® (DaxibotulinumtoxinA-lanm) injection IMPORTANT SAFETY INFORMATION INDICATIONS DAXXIFY® (DaxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults. Please see DAXXIFY® full Prescribing Information , including Boxed Warning and Medication Guide . To report side effects associated with DAXXIFY®, please visit safety.revance.com , or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch . [DAXI-004726] About DAXXIFY® DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection is the first and only FDA-approved, long-lasting, peptide-formulated neuromodulator product with approved indications in the U.S. for the temporary improvement of glabellar lines (frown lines) and for the treatment of cervical dystonia in adults. DAXXIFY® is powered by Peptide Exchange Technology™, Revance's proprietary, synthetic, 35-amino-acid stabilizing excipient, and is developed free of human serum albumin or animal-based components. 3,4 Manufactured in the U.S., DAXXIFY® is the first true innovation in neuromodulator product formulation in over 30 years. About Revance Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers in the U.S., and value-added services including the OPUL® Relational Commerce platform for aesthetic practices. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY® in China. Revance is headquartered in Nashville, Tenn., with additional office locations in Newark and Irvine, Calif. Learn more at www.Revance.com , www.RevanceAesthetics.com , www.DAXXIFY.com , https://hcp.daxxify.com/ , or connect with us on LinkedIn . “Revance” and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA. About Cervical Dystonia Cervical dystonia is a painful condition in which the neck muscles contract involuntarily, causing abnormal movements and awkward posture of the head and neck. The movements may be sustained (tonic), jerky (clonic), or a combination. Cervical dystonia (also referred to as spasmodic torticollis) may be primary (meaning that it is the only apparent neurological disorder, with or without a family history) or may be the result of secondary causes (such as physical trauma). First-line treatment for cervical dystonia is usually neuromodulator (botulinum toxin) injections, but additional treatments can include oral medications, surgery, and complementary therapies. Neuromodulators block the communication between the nerve and the muscle, relaxing the muscle, which alleviates abnormal involuntary movements and postures. Cervical dystonia can occur at any age, although most individuals first experience symptoms in middle age. Roughly 60,000 Americans suffer from this muscle movement disorder. SOURCES SOURCE: Revance Therapeutics

Robert Barrie As per Revance, Daxxify should be available at the beginning of 2024. Image credit: Shutterstock/Elnur. Revance Therapeutics has entered the cervical dystonia treatment arena after the US Food and Drug Administration (FDA) approved Daxxify (daxibotulinumtoxinA-lanm) for the neck condition, which is characterised by involuntary muscle contractions. Botulinum toxins are considered the first line of treatment for cervical dystonia and work by blocking nerve and muscle signalling pathways. Already approved for use in the treatment space are AbbVie ’s Botox (onabotulinumtoxinA), Galderma ’s Dysport (abobotulinumtoxina), Merz Pharmaceuticals’ Xeomin (incobotulinumtoxinA), and US WorldMeds’ Myobloc (rimabotulinumtoxinb). Recommended Reports Reports LOA and PTSR Model - Zoliflodacin in Uncomplicated Cervical And Urethral Gonorrhea GlobalData Reports LOA and PTSR Model - Medchew Dronabinol in Chemotherapy Induced Nausea and Vomiting GlobalData View all Companies Intelligence AbbVie Inc Galderma SA Revance Therapeutics Inc Aspen View all As per Revance, Daxxify should be available at the beginning of 2024. Daxxify is a peptide-formulated neuromodulator that was previously approved for aesthetic use in the improvement of glabellar (frown) lines. The popularity of AbbVie’s Botox has meant the drug’s name has effectively become synonymous with the treatment for wrinkles and has enjoyed market domination for a few decades. Still, Revance says Daxxify has an advantage over other alternatives since it is longer lasting. With Daxxify’s label expansion by the FDA, the company will now renew its rivalry with AbbVie in cervical dystonia treatment. Revance says the therapeutic neuromodulator market opportunity for Daxxify is $2.5bn – of which $345m is contributed by the cervical dystonia market. The FDA based its approval on data from the ASPEN clinical programme which demonstrated that Daxxify improved symptoms with a median duration of 24 weeks at 125U dosing. ASPEN investigator and co-founder and the New England Institute for Neurology and Headache medical director Dr Peter McAllister said: “Currently, patients experience painful and life-limiting symptom recurrence as early as eight to ten weeks in clinical practice but cannot be re-treated until 12 weeks. “Daxxify is the first long-acting neuromodulator that has the potential to address this significant unmet need – demonstrating durable symptom relief between treatment cycles and providing the opportunity to extend treatment intervals.”